Company intelligence / Profile preview

Cybin Inc.

Ownership: Public · CYBN
Development stage: Phase 3

Overview

Cybin has reported positive Phase 2 data for CYB003, demonstrating breakthrough 12-month efficacy in treating Major Depressive Disorder. The company has received FDA Breakthrough Therapy Designation for CYB003 and is advancing to a multinational Phase 3 program called PARADIGM.

Therapeutic areas: PsychiatryNeurology
Modalities: Psychedelic-based therapeuticsDeuterated tryptaminesNovel drug delivery systems
Industry: Biotech

Drug pipeline

11 assets

CYB003

10 more assets in the full pipeline.

Request access →

Partnerships

Kernel

Financials

Market cap: $413M
Total revenue: $0
Enterprise value: $358.2M

Beyond the preview

Go deeper on Cybin Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cybin Inc..

Explore the full profile